By comprehensively analysing the expression profile of RFX1 in pan-cancer, we found that RFX1 has higher expression in digestive tract tumors, including colon, cholangiocarcinoma and gastric cancer, compared to normal paraneoplastic tissues (Fig. 1A). This evidence concerns the gene RFX1 and cholangiocarcinoma.